specialistcannabinoids

University Specialist Course in the Use of Cannabis and Cannabinoid Derivatives

PRESENTATION

OBJECTIVES

The main objective of this University Specialist Degree in Cannabis and Cannabinoid Derivatives is to provide unequivocal, clear and contrasted information from an academic and scientific point of view about cannabis, natural and synthetic cannabinoid derivatives, and the endogenous cannabinoid system that can be useful for a wide range of professionals in both public centres and private companies with an interest in cannabinoids.

This idea can be summarised in the following specific objectives:

  • To train specialists in academic, educational centres of public and private organisations capable of transmitting truthful and contrasted information on cannabis and cannabinoid derivatives.
  • To train specialists who can initiate or extend scientific research of national and international interest in public and private research centres on a wide range of aspects related to cannabinoids.
  • To train clinical specialists from different medical and pharmaceutical specialties in the approved, clinically tested and potentially useful therapeutic properties of natural and synthetic cannabinoids and endogenous ligand modulating drugs in order to be able to make therapeutic decisions based on proven scientific evidence.
  • To train patent experts in the information necessary to acquire sufficient knowledge to regulate or reject cannabinoid products that are submitted by pharmaceutical companies for evaluation and subsequent sale on the national and international market.

COURSE DETAILS

Section 0. Introduction

Introduction. Cannabis: therapeutic or recreational drug

Prof. Jorge Manzanares Robles, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 

Section 1. Botany, pharmacognosy, pharmacology and recreational use of the cannabis plant

Lecture 1.1. History of cannabis, from its origins to today’s products

Prof. Javier Muriel Serrano, Department of Pharmacology, Pediatrics and Organic Chemistry, Universidad Miguel Hernández, Spain

Lecture 1.2. Taxonomy and botany of cannabis. Macroscopic and microscopic characteristics

Prof. Javier Muriel Serrano, Department of Pharmacology, Pediatrics and Organic Chemistry, Universidad Miguel Hernández, Spain

Lecture 1.3. Phytochemistry of cannabis: main families of compounds and their main pharmacological uses

Prof. Javier Muriel Serrano, Department of Pharmacology, Pediatrics and Organic Chemistry, Universidad Miguel Hernández, Spain

Lecture 1.4. Main analytical techniques for the characterization of cannabis compounds. Good Laboratory Practices (GLP)

Prof. Enrique Barrajón Catalán, Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universidad Miguel Hernández, Spain

 Lecture 1.5. Techniques for the extraction of active compounds from cannabis

Prof. Enrique Barrajón Catalán, Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universidad Miguel Hernández, Spain

 Lecture 1.6. Pharmacology of cannabinoids (endogenous ligands, receptors, synthesis and degradation enzymes)

Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 1.7. Cannabinoid signaling in the brain: extracting specificity from ubiquity

Prof. Giovanni Marsicano, NeuroCentre Magendie INSERM, University of Bordeaux, France

 

Section 2. Alterations of the cannabinoid system in animal experimentation and clinical pathology

Lecture 2.1. Endocannabinoid System Components as potential biomarkers

Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.2. Immunohistochemistry, conventional and confocal microscopy, western blots (localization, antibodies, dimerization, colocalization, etc.)

Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.3. Methodology for detecting changes in ECS components: gene expression, polymorphisms and epigenetics.

Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.4. Methodology for detecting changes in ECS components: biochemistry

Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.5. Methods for detecting changes in the endocannabinoid system: neuroimaging (PET, SPECT, fMRI)

Prof. Silvia de Santis, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.6. Alterations of the endocannabinoid system in gastrointestinal diseases

Prof. Ani Gasparyan Hovhannisyan, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.7. Alterations of the endocannabinoid system in liver diseases

Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.8. Alterations of the endocannabinoid system in renal diseases

Prof. María Salud García Gutiérrez, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.9. Alterations of the endocannabinoid system in endocrinology

Prof. Ani Gasparyan Hovhannisyan, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.10. Alterations of the endocannabinoid system in respiratory diseases

Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.11. Alterations of the endocannabinoid system in oncology

Prof. Ana Lucía Yuste, Oncology Department, General Hospital of Alicante, Spain

 Lecture 2.12. Changes in the endocannabinoid system in pain and inflammation

Prof. Katarzyna Starowicz, Maj Institute of Pharmacology Polish Academy of Sciences, Poland

 Lecture 2.13. Alterations of the endocannabinoid system in neurology

Prof. Ani Gasparyan Hovhannisyan, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 2.14. Alterations of the endocannabinoid system in psychiatry

Prof. María Salud García Gutiérrez, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 

Section 3. Therapeutic uses of cannabinoid derivatives I (pain, neurology and psychiatry)

Lecture 3.1. Therapeutic applications of cannabinoids in pain management

Prof. Raquel Saldaña, Anaesthesia Section at Hospital 12 De Octubre, Spain

Lecture 3.2. Therapeutic applications of cannabinoids in the management of neuropathic pain

Prof. Katarzyna Starowicz. Maj Institute of Pharmacology Polish Academy of Sciences, Poland

Lecture 3.3. Cannabinoid therapy in epilepsy and epileptic syndromes

Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.4. Multiple sclerosis: role of cannabinoids in treatment and pathophysiological aspects

Prof. María Salud García Gutiérrez, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.5. Cannabinoids and extrapyramidal pathology: Parkinson’s disease and other extrapyramidal diseases (dystonia, Gilles Tourette syndrome, tics, etc.).

Prof. Ani Gasparyan Hovhannisyan, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.6. Role of cannabinoids in migraine

Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.7. Therapeutic usefulness of cannabinoids in anxiety and depressive disorders

Prof. María Salud García Gutiérrez, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.8. Role of cannabinoid CB2 receptor in the regulation of emotional and addictive behaviors

Prof. Jorge Manzanares Robles, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.9. Role of cannabidiol and sertraline in regulating behavioral and brain gene expression changes in a novel animal model of posttraumatic stress disorder

Prof. Jorge Manzanares Robles, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Lecture 3.10. Role of cannabidiol in drug dependence

Prof. Jorge Manzanares Robles, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 

 Section 4. Therapeutic uses of cannabinoid derivatives II (oncology, endocrinology, cardiology, respiratory, digestive, ophthalmology, dermatology, skeletal system, others)

Lecture 4.1. Regulation of the immune system by cannabinoids: inflammation and infection

Prof. Esther Caparrós Cayuela, Deparment Clinical Medicine, Universidad Miguel Hernández, Spain

Lecture 4.2. Cannabinoid products as immunomodulators: clinical trials and animal modeling

 Prof. Esther Caparrós Cayuela, Deparment Clinical Medicine, Universidad Miguel Hernández, Spain

 Lecture 4.3. Cannabinoid system-intestinal microbiome relationship: physiology and pathology

 Prof. Esther Caparrós Cayuela, Deparment Clinical Medicine, Universidad Miguel Hernández, Spain

 Lecture 4.4. Utility of cannabinoid therapy in cardiovascular pathology

 Prof. María Salud García Gutiérrez, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.5. Role of the endocannabinoid system in energy balance and obesity

 Prof. Daniela Cota, NeuroCentre Magendie INSERM, University of Bordeaux, France

 Lecture 4.6. Therapeutic potential of the use of cannabinoid compounds in the treatment of renal pathologies

 Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.7. Potential therapeutic utility of cannabinoid compounds in liver diseases

 Prof. Ani Gasparyan Hovhannisyan, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.8. Potential therapeutic utility of cannabinoid compounds in respiratory pathologies

 Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.9. Usefulness of the use of cannabinoids in traumatology

 Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.10. Effects of cannabinoids on bone tissue

 Prof. Daniela Navarro, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.11. Potential therapeutic utility of cannabinoid compounds in genitourinary disorders

 Prof. Ani Gasparyan Hovhannisyan, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.12. Therapeutic potential of the use of cannabinoid compounds in the treatment of ophthalmologic pathologies

 Prof. Francisco Navarrete Rueda, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

 Lecture 4.13. Cannabinoids in dermatology

 Prof. María Salud García Gutiérrez, Institute of Neurosciences, CSIC/Universidad Miguel Hernández, Spain

Section 5. Patents and cannabinoid research seminar

Patent Seminar. Patents related to cannabinoid compounds

Prof. Ramón Soto, National Autonomous University of Mexico, Mexico

Research Seminar. Genetically modified mice in neuropsychopharmacology research

Prof. Jan Rodríguez Parkitna, Maj Institute of Pharmacology Polish Academy of Sciences, Poland

Course Schedule 

Sections 0 and 1: start 4th December 23

Section 2: Start 22nd January 24

Section 3: Start 18th March 24

Section 4: Start 13th May 24

Section 5: Start 1st July 24

CERTIFICATION

The contents taught in the form of knowledge pills (audiovisual) will be evaluated after each thematic block (clinical case, discussion forum and a questionnaire).

To access the content you must be registered for the course (free of charge at http://www.specalistcannabinoids.umh/).

Passing these evaluations will entitle the student to the Director’s Certification of the course, equivalent to 75 hours.